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The ankle-brachial index (ABI) is the ratio of the systolic
blood pressure measured at the ankle divided by the systolic
blood pressure at the arm. By convention, the highest of the
2 arm pressures and the highest of the dorsalis pedis or
posterior tibial artery pressures at the ankle are used to form
the calculation, with peripheral artery disease (PAD) iden-
tiﬁed at a threshold of an ABI 0.90 in either leg (the index
leg would have the lowest ABI) (1). The ABI essentially
measures the hemodynamic severity of occlusive disease in
the lower extremity. Thus, the measure would miss early
atherosclerotic lesions, because an abnormal ABI is depen-
dent upon a pressure drop across a signiﬁcant arterial stenosis
or occlusion to reduce the pressure at the ankle. A lower ABI
value is associated with greater hemodynamic disease burdenSee page 553usually involving multiple occlusions between the aorta and
the tibial vessels.
The historical utility of the ABI has been as the primary
noninvasive means to diagnose PAD in the setting of
evaluating patients with limb signs or symptoms suggestive
of PAD. In patients with an isolated, proximal iliac stenosis
who have a normal ABI, an exercise test is often employed to
bring out the hemodynamic abnormality. In this setting
an abnormal ABI in conjunction with an appropriate con-
solation of symptoms would lead to a cascade of interven-
tions to treat those symptoms. This could range from general
measures to treat the underlying atherosclerosis of the
patient to a formal exercise program, claudication medica-
tions, or re-vascularization to relieve the symptoms. Patients
with critical limb ischemia have signiﬁcant hemodynamic
compromise and usually move straight to revascularization
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PAD because of concerns about false positive results and
unnecessary evaluations (3). In contrast, the American
College of Cardiology Foundation/American Heart Asso-
ciation guidelines for PAD provide a Class 1b recommen-
dation for ABI screening in subjects at risk for PAD (4).
More recently, the ABI has been identiﬁed as a measure
that aids in risk assessment and prediction of cardiovascular
events (5). Patients with PAD have a systemic disorder that
is highly correlated with coronary and carotid artery disease
with associated increased risk of myocardial infarction,
stroke, and vascular death. When applied as a risk prediction
tool, an ABI <1.00 is associated with an increase in
cardiovascular risk that is progressively magniﬁed at lower
ABI values. When evaluated across a number of epidemio-
logic studies and in the context of a clinical Framingham risk
score, an abnormal ABI was able to re-classify the risk
category and risk recommendations in 19% of men and 36%
of women (5). Thus, the ABI provided independent infor-
mation over and above a clinical cardiovascular risk score.
As noted in the preceding text, the calculation of ABI has
been generally based on assessing the higher of the 2 ankle
pressures. The logic is to estimate the highest perfusion
pressure in the limb and also to avoid over-diagnosis
particularly if the higher value is in the normal range and
the lower ankle pressure value is abnormal. In that setting
the patient might have isolated tibial disease, which might
not be symptomatic. However, a recent scientiﬁc statement
from the American Heart Association did recommend
considering the lower of the 2 pressures as perhaps a better
method to risk-stratify individuals (1).
In this context, the study by Nead et al. (6) in this issue of
the Journal provides critical new information on the prog-
nostic value of an alternative method to calculate the ABI.
This investigation was conducted across 2 academic institu-
tions; patients were recruited who were undergoing an
elective nonemergent coronary angiogram for evaluating
cardiac symptoms. In these subjects the ABI was determined
from both the higher and the lower of the ankle pressures,
deriving a traditional (higher) and alternative (lower) ABI
value, and patients were followed for subsequent cardiovas-
cular events. The results demonstrated that approximately
16% of this referral population had an abnormal ABI by the
traditional measure; however, an additional 21% had an
abnormal ABI by the alternative calculation (these were
mutually exclusive populations). An abnormal ABI by the
alternative method would imply that those subjects had
isolated tibial artery disease, because the higher pressure of
the 2 tibial vessels would have resulted in an ABI in the
normal range. When followed for cardiovascular outcomes,
both methods had similar diagnostic and predictive accuracy
for all-cause and cardiovascular mortality with similar hazard
ratios between the methods. However, the C-index sug-
gested slightly better diagnostic characteristics for the alter-
native method predicting cardiovascular mortality. But the
primary message is that the alternative method identiﬁed
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ered at risk on the basis of the ﬁnding that their traditional
ABI was normal. Therefore, the main utility of the alternate
method is to identify an additional at-risk population for
cardiovascular events that would have otherwise been missed.
These ﬁndings are provocative and could potentially
change our approach to calculating the ABI when used as
an index of cardiovascular risk. However, the ﬁndings are
limited, because this was a referral population primarily
evaluated for potential coronary disease, and the vast ma-
jority of subjects were also identiﬁed as having underlying
coronary disease. Conﬁrmatory studies on the alternative
ABI calculation would need to be performed in broader
populations.
The implication of these ﬁndings is that an abnormal ABI
calculation in either extremity with the lower of the tibial
vessel pressures seems to be highly correlated with increased
cardiovascular risk and mortality. Therefore, in the context of
using the ABI as an objective measure to identify subclinical
atherosclerosis, even isolated tibial occlusive disease is highly
correlated with adverse cardiovascular outcomes. This ﬁnding
could signiﬁcantly broaden the utility of the ABI as a risk
stratiﬁcation measure.
Perhaps more important is the general perception of the
utility of the ABI. As noted in the preceding text, the U.S.
Preventive Services Task Force recommends against ABI
screening of asymptomatic populations for concern that the
information would lead to inappropriate work-up and
excessive use of peripheral procedures (despite no data to
support this concern). In contrast, cardiovascular guidelines
(TransAtlantic Inter-Society Concensus and American
College of Cardiology Foundation/American Heart Associ-
ation) provide a strong recommendation for ABI screening.
The current study further conﬁrms the importance of
measuring peripheral hemodynamic status and assessing
populations at potential risk to further reﬁne their riskprediction and also appropriately target risk reduction
interventions. A limitation of the ABI is that its utility has
not been formally tested in a randomized controlled trial with
a design that uses ABI as the entry point to assess outcomes.
However, in the absence of this information, the current
utility as a risk prediction tool is certainly well-established,
and that utility has been further validated by the current
study.
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